Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 7/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794452 | 1.00 | GRM1 (0.51) | GRM1HDAC6PDGFRBKDRPTGER4 | |
| SCHEMBL30795858 | 0.90 | GRM1 (0.40) | GRM1HDAC6PTGER4SCN10AKCNQ2 | |
| SCHEMBL2679946 | 0.90 | GRM1 (0.40) | GRM1HDAC6PTGER4SCN10AKCNQ2 | |
| SCHEMBL2680089 | 0.87 | PTGER4 (0.46) | GRM1HDAC6PTGER4SCN10AGRIN2D | |
| SCHEMBL30795847 | 0.87 | PTGER4 (0.46) | GRM1HDAC6PTGER4SCN10AGRIN2D | |
| SCHEMBL2679951 | 0.87 | PTGER4 (0.41) | GRM1HDAC6PTGER4SCN10AKCNQ2 | |
| SCHEMBL2680430 | 0.87 | PTGER4 (0.41) | GRM1HDAC6PTGER4NAMPTSCN10A | |
| SCHEMBL30796044 | 0.87 | PTGER4 (0.41) | GRM1HDAC6PTGER4NAMPTSCN10A | |
| SCHEMBL30794520 | 0.87 | PTGER4 (0.41) | GRM1HDAC6PTGER4SCN10AKCNQ2 | |
| SCHEMBL694515 | 0.87 | GRM1 (0.50) | GRM1HDAC6PDGFRBKDRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | KCNQ1, KCNQ2, KCNQ5 | GRM1 1529/4885HDAC6 1621/4885PDGFRB 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.